Onco Wiki / Indication

Ovarian carcinoma (high-grade serous predominant) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackstandard
Linked regimenNone
IDIND-RAD51C-D-CARRIER-PREVENTION-SURVEILLANCE
TypeIndication
Statusreviewed 2026-05-19 | pending_clinical_signoff
DiseasesDIS-OVARIAN
SourcesSRC-NCCN-BREAST-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 SRC-NCCN-OVARIAN-2025

Notes

STUB — v0.3 moderate-penetrance panel prevention expansion. Two-Co-Lead signoff queued per CHARTER §6.1 dev-mode.

Used By

Indication